The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Yes I see , So the claims will be ‘maintains healthy blood flow ‘ and lowers blood pressure ‘
"The two completed studies (a human study and an animal study) showed excellent results in use for Fruitflow®,
and BY-HEALTH intends to make its first blue cap submission to the SAMR for Fruitflow® in February 2019,
with a further blue cap submission envisaged later in 2019, both to include references to the Company’s
existing European Food Safety Authority (‘EFSA’) health claim for Fruitflow."
https://provexis.org/wp-content/uploads/2018/12/PXS_2018-11_Provexis_plc_30-Sep-18_interims_31-Dec-18.pdf
Sphinx, I am hoping that the studies are for more than one health claim. Guessing blood pressure reduction being one.
An earlier RNS did indicate to at least 2.
Gixer I’m not sure it has been delayed, in the interims they stated that 5 studies are complete 2 are ongoing and 2 will take place In 2020 9 in all , so as we discussed before do they need all 9 studies to be complete before Blue hat approval is given ! My gut feeling is that they don’t need all 9 approved ,but each study would add strength to the case for efficacy for ff.
"Although the article is a year old it could explain the delay for at least one health claim."
delay is the wrong word to use as we don't know that there is one. However it would be nice if the company could give us a bit more info on Blue Hat.
Thanks Bella,
Although the article is a year old it could explain the delay for at least one health claim.
"the review also suggested to relook health claims that require further research evidence. Six claims, which include “aids in lowering of blood pressure” ?and “aids in lowering of blood sugar”?, would be affected."
"Regulatory advice ?
Regulatory experts have advised manufacturers to halt the R&D of products that bear claims which may require additional scientific research. This was because these claims might not be approved eventually, thus, if manufacturers were to proceed with R&D of these products, their past efforts would go down the drain, Charles Diao, regulatory manager at US-China Health Products Association told NutraIngredients-Asia."
https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2020077747&_cid=P10-K9F8JJ-45635-1
Bella that article is 14 months old
Gixer I think you have answered your own question , by health ( bought) Life space in 2018 , they had a working relationship with them for years before , by health have a vested interest in promoting brands they own , still looking good for pxs imo
Life-Space was bought by By-Health on the 30th of August 2018 and already have dual health-care functions of "regulating intestinal flora" and "boosting immunity”
Provexis and DSM partnered with By-Health on the 18 November 2016 and we still dont have any health claims :(
I can only think that probiotics were already approved in China making it quicker and easier for By-Health to get the approvals.
It looks like when they get SAMR approvals they are going to push this throughout the country ,looking great imo
No mention of ff but very positive. Since the first quarter, facing the severe external environment, the Company had positively made a response and adjustment, in the anticipation to maintain relatively stable operations. As the domestic consumer markets gradually recover in the second quarter, the Company will implement the established market strategy to comprehensively facilitate product lines based on the "four hero products two image products one star product" structure, so as to the activate consumer demand. Promotion efforts on master brand "BY-HEALTH" will be increased in the second quarter, in close integration with the "boosting immunity" trend, to achieve the growth and expansion of market for protein powder and vitamin products. BY-HEALTH, as the industrial leader, will then drive the rapid growth of the entire product category. Hero product "Keylid" for joint care launched a new round of promotion in April to boost the regional terminal sales. At the same time, Life-Space was also approved as the health food with dual health-care functions, namely "regulating intestinal flora" and "boosting immunity” at the beginning of the year, and launched in March. With the "hero product" strategy aiming to create another "Keylid", Life-Space will also gradually increase market investment in the second quarter to continuously enhance the brand effect. On the basis of three existing hero products, brand new liver care product "Jianganshi" is launched on a blue ocean market - liver care market, and promotes sales through pharmacy channels relying on hard-to-get approvals and compound formulas as its unique advantages.